Researcher
Pieter Van Der Veken
- Research Expertise:Medicinal chemistry & drug discovery, pharmaceutical chemistry, organic chemistry & organic synthesis
- Keywords:ORGANIC CHEMISTRY, MEDICINAL CHEMISTRY, DRUG DISCOVERY, Pharmacy and pharmacology
- Disciplines:(Bio)molecular modelling and design, Characterisation of biologically active (macro)molecules, Medicinal and biomolecular chemistry not elsewhere classified, Bio-organic chemistry, Organic chemical synthesis, Medicinal chemistry
- Research techniques:Drug design, organic synthesis, characterization of molecules via NMR spectroscopy, mass spectrometry and other analytical techniques
- Users of research expertise:Pharmaceutical and biotech-industry
Affiliations
- Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2003 → Today
Projects
1 - 10 of 74
- Druglike FAPIs with maximal target residence time: chemical discovery and biological characterization.From1 Jan 2024 → TodayFunding: IOF - technology concept exploration
- Potent intra-tumoral autophagy blocking with kinase PROTACs and inhibitors.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Cell-type specific delivery of autophagy inducers as a strategy to address localized autophagy impairment in diseaseFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Directed optimization of highly selective DPP9 inhibitors for chemical biology and translational research.From1 Nov 2023 → TodayFunding: FWO fellowships
- Characterization and validation of novel autophagy inducers identified via high-throughput screening: a therapeutic option for the treatment of advanced atherosclerosis.From1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- AUTAC- and PROTAC-mediated degradation of DPP9 to induce pyroptosis: a novel treatment strategy in acute myeloid leukemia.From1 Oct 2023 → TodayFunding: FWO junior postdoctoral fellowship
- Development of a pancreatic cancer drug-nanocarrier system selectively targeting tumour cells and tumour stroma to overcome treatment failure (PaCaNano).From1 Sep 2023 → TodayFunding: FWO research project (including WEAVE projects)
- OncoProToolsFrom1 Jun 2023 → TodayFunding: BOF - projects
- DPP9 degradation-induced pyroptosis for treatment of acute myeloid leukemia (DPP9-TACDrug).From1 Apr 2023 → TodayFunding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Diagnostic and theranostic targeting of fibroblast activation protein (FAP) with goed nanoparticles decorated with FAPIs and FAPI fragments.From1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
Publications
31 - 40 of 129
- A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation(2020)
Authors: Cedric Joossen, Adrienn Baán, Carlos Moreno Cinos, Jurgen Joossens, Nathalie Cools, Ellen Lanckacker, Lieve Moons, Kim Lemmens, Anne-Marie Lambeir, Erik Fransen, et al.
Pages: 1 - 14 - Caspase-3 probes for PET imaging of apoptotic tumor response to anticancer therapy(2019)
Authors: Tom Vanden Berghe, Yves Adriaenssens, Peter Vandenabeele, Koen Augustyns, Steven Staelens, Sigrid Stroobants, Pieter Van Der Veken, Leonie Wyffels
Pages: 4801 - 4824 - DPP8/DPP9 inhibition elicits canonical Nlrp1b inflammasome hallmarks in murine macrophages(2019)
Authors: Nathalia M. Vasconcelos, Gwendolyn Vliegen, Amanda Gonçalves, Emilie De Hert, Rosa Martín-Pérez, Nina Van Opdenbosch, Anvesh Jallapally, Ruth Geiss-Frielander, Anne-Marie Lambeir, Koen Augustyns, et al.
- α-amino diphenyl phosphonates as novel inhibitors of Escherichia coli ClpP protease(2019)
Authors: Carlos Moreno Cinos, Elisa Sassetti, Irene Garcìa Salado, Gesa Witt, Siham Benramdane, Laura Reinhardt, Cristina D. Cruz, Jurgen Joossens, Pieter Van Der Veken, Heike Broetz-Oesterhe, et al.
Pages: 774 - 797 - Novel small molecule-derived, highly selective substrates for fibroblast activation protein (FAP)(2019)
Authors: An De Decker, Gwendolyn Vliegen, Dries Van Rompaey, Anke Peeraer, An Bracke, Line Verckist, Koen Jansen, Ruth Geiss-Friedlander, Koen Augustyns, Hans De Winter, et al.
Pages: 1173 - 1179 - Improved stability of a novel fluorine-18 labeled TCO analogue for pretargeted PET imaging(2019)
Authors: Eduardo Ruivo, Karuna Adhikari, Filipe Elvas, Jens Fissers, Christel Vangestel, Steven Staelens, Sigrid Stroobants, Pieter Van Der Veken, Leonie Wyffels, Koen Augustyns
Pages: 36 - 42 - Synthesis and evaluation of novel benzotropolones as Atg4B inhibiting autophagy blockers(2019)
Authors: Muhammet Tanc, Matthias Cleenewerck, Ammar Kurdi, Ria Roelandt, Wim Declercq, Guido De Meyer, Koen Augustyns, Wim Martinet, Pieter Van Der Veken
Pages: 163 - 168 - Spatiotemporal expression and inhibition of prolyl oligopeptidase contradict its involvement in key pathologic mechanisms of kainic acid–induced temporal lobe epilepsy in rats(2019)
Authors: Idrish Ali, Annemie Van Eetveldt, Roos Van Elzen, Tom Kalathil Raju, Pieter Van Der Veken, Anne-Marie Lambeir, Stefanie Dedeurwaerdere
Pages: 92 - 101 - Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma(2019)
Authors: Andrew J. Gunderson, Tomoko Yamazaki, Kayla McCarty, Michaela Phillips, Alejandro Alice, Shelly Bambina, Lauren Zebertavage, David Friedman, Benjamin Cottam, Pippa Newell, et al.
- The development and validation of a combined kinetic fluorometric activity assay for fibroblast activation protein alpha and prolyl oligopeptidase in plasma(2019)
Authors: An Bracke, Roos Van Elzen, Pieter Van Der Veken, Koen Augustyns, Ingrid De Meester, Anne-Marie Lambeir
Pages: 154 - 160
Patents
1 - 10 of 10
- 3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)